Original Research

Published on 04 Jul 2023

Unresectable stage III non-small cell lung cancer: could durvalumab be safe and effective in real-life clinical scenarios? Results of a single-center experience

in Thoracic Oncology

Paolo Borghetti
Giulia Volpi
Giorgio Facheris
Gianluca Cossali
Eneida Mataj
Salvatore La Mattina
Navdeep Singh
Jessica Imbrescia
Marco Lorenzo Bonù
Davide Tomasini

Frontiers in Oncology

doi 10.3389/fonc.2023.1208204

3,403 views
2 citations

Original Research

Published on 04 Jul 2023

Camrelizumab as a novel third or post-third-line treatment strategy in small cell lung cancer: a retrospective study of 12 patients

in Thoracic Oncology

Jizheng Tian
Lili Sui
Hong Wang
Xiaoyan Chen

Frontiers in Oncology

doi 10.3389/fonc.2023.1180735

1,171 views
2 citations

Case Report

Published on 03 Jul 2023

Long-lasting benefit on multimodal treatment combining osimertinib and stereotaxic radiotherapy for metastatic non-small cell lung cancer with the EGFR exon 20 insertion 773-774 HVdelinsLM: a case report

in Thoracic Oncology

Aurélie Louvet
Natasha Honoré
Anne-France Dekairelle
Cédric Van Marcke
Jean-Charles Goeminne

Frontiers in Oncology

doi 10.3389/fonc.2023.1143775

1,616 views

Original Research

Published on 30 Jun 2023

A tumor mutational burden-derived immune computational framework selects sensitive immunotherapy/chemotherapy for lung adenocarcinoma populations with different prognoses

in Thoracic Oncology

Wenlong Zhang
Chuzhong Wei
Fengyu Huang
Wencheng Huang
Xiaoxin Xu
Xiao Zhu

Frontiers in Oncology

doi 10.3389/fonc.2023.1104137

2,541 views
8 citations

Case Report

Published on 28 Jun 2023

Therapeutic strategies to overcome EGFR mutations as acquired resistance mechanism in ALK-rearranged non-small-cell lung cancer: Case Reports

in Thoracic Oncology

Lionel Michaux
Alexandre Perrier
Camille Mehlman
Hussa Alshehhi
Antonin Dubois
Roger Lacave
Florence Coulet
Jacques Cadranel
Vincent Fallet

Frontiers in Oncology

doi 10.3389/fonc.2023.1182558

2,243 views
4 citations

Original Research

Published on 27 Jun 2023

RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC

in Thoracic Oncology

Qian Wang
Tao Yu
Zi-Hao Ke
Fu-Feng Wang
Jia-Ni Yin
Yang Shao
Kai-Hua Lu

Frontiers in Oncology

doi 10.3389/fonc.2023.1172728

2,270 views
1 citation

Original Research

Published on 23 Jun 2023

Immune microenvironment analysis and novel biomarkers of early-stage lung adenocarcinoma evolution

in Thoracic Oncology

Jun Liu
Yaxin Ji
Xiaodan Weng
Wei Shao
Jiaping Zhao
Hanlin Chen
Lu Shen
Fufeng Wang
Qi Meng
Xue Wu

Frontiers in Oncology

doi 10.3389/fonc.2023.1150098

2,023 views

Editorial

Published on 22 Jun 2023

Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC

in Thoracic Oncology

Umberto Malapelle
Fabrizio Tabbò
Lucia Anna Muscarella

Frontiers in Oncology

doi 10.3389/fonc.2023.1239304

660 views

Systematic Review

Published on 20 Jun 2023

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports

in Thoracic Oncology

Liang Shi
Shuhong Gao
Li Tong
Qiyi Meng
Shijie Zhou
Daping Yu
Yujie Dong
Zhe Liu

Frontiers in Oncology

doi 10.3389/fonc.2023.1120511

1,886 views
1 citation

Original Research

Published on 20 Jun 2023

Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment

in Thoracic Oncology

Cheng-Yu Chang
Chung-Yu Chen
Shih-Chieh Chang
Ching-Yi Chen
Yi-Chun Lai
Chun-Fu Chang
Yu-Feng Wei

Frontiers in Oncology

doi 10.3389/fonc.2023.1104098

1,849 views

Original Research

Published on 19 Jun 2023

Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer

in Thoracic Oncology

Veronika Pelicon
Tanja Cufer
Lea Knez

Frontiers in Oncology

doi 10.3389/fonc.2023.1182748

3,331 views
1 citation

Original Research

Published on 16 Jun 2023

Quantitative proteomics identifies tumour matrisome signatures in patients with non-small cell lung cancer

in Thoracic Oncology

Helen F. Titmarsh
Alex von Kriegsheim
Jimi C. Wills
Richard A. O’Connor
Kevin Dhaliwal
Margaret C. Frame
Samuel B. Pattle
David A. Dorward
Adam Byron
Ahsan R. Akram

Frontiers in Oncology

doi 10.3389/fonc.2023.1194515

2,262 views
3 citations

Editorial

Published on 16 Jun 2023

Editorial: Application of nanotechnology in diagnosis and/or therapy of non-small cell lung cancer

in Thoracic Oncology

Qinglin Shen
Ling Peng
Yi Zhang
Ruoxiang Wang

Frontiers in Oncology

doi 10.3389/fonc.2023.1234727

820 views

Original Research

Published on 15 Jun 2023

A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study

in Thoracic Oncology

Salvador Fudio
Laura Pérez-Ramos
Eduardo Asín-Prieto
Ali Zeaiter
Rubin Lubomirov

Frontiers in Oncology

doi 10.3389/fonc.2023.1152371

1,942 views
1 citation

Correction

Published on 14 Jun 2023

Corrigendum: Efficacy of modified thoraco-laparoscopic Ivor-Lewis versus traditional thoraco-laparoscopic Ivor-Lewis for esophageal cancer: propensity score-matched analysis

in Thoracic Oncology

Ziqiang Hong
Wenxi Gou
Yingjie Lu
Xusheng Wu
Yannan Sheng
Baiqiang Cui
Xiangdou Bai
Dacheng Jin
Yunjiu Gou

Frontiers in Oncology

doi 10.3389/fonc.2023.1216836

723 views

Perspective

Published on 14 Jun 2023

Addressing the unmet need for a comprehensive lung cancer registry in Romania

in Thoracic Oncology

Gheorghe-Emilian Olteanu
Cristian Iulian Oancea
Marian Catalin
Adrian Pavel Trifa
Stefan Dascalu

Frontiers in Oncology

doi 10.3389/fonc.2023.1211533

2,064 views
1 citation

Navigation group

Articles

Unresectable stage III non-small cell lung cancer: could durvalumab be safe and effective in real-life clinical scenarios? Results of a single-center experience

Camrelizumab as a novel third or post-third-line treatment strategy in small cell lung cancer: a retrospective study of 12 patients

Long-lasting benefit on multimodal treatment combining osimertinib and stereotaxic radiotherapy for metastatic non-small cell lung cancer with the EGFR exon 20 insertion 773-774 HVdelinsLM: a case report

A tumor mutational burden-derived immune computational framework selects sensitive immunotherapy/chemotherapy for lung adenocarcinoma populations with different prognoses

Therapeutic strategies to overcome EGFR mutations as acquired resistance mechanism in ALK-rearranged non-small-cell lung cancer: Case Reports

RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC

Immune microenvironment analysis and novel biomarkers of early-stage lung adenocarcinoma evolution

Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports

Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment

Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer

Quantitative proteomics identifies tumour matrisome signatures in patients with non-small cell lung cancer

Editorial: Application of nanotechnology in diagnosis and/or therapy of non-small cell lung cancer

A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study

Corrigendum: Efficacy of modified thoraco-laparoscopic Ivor-Lewis versus traditional thoraco-laparoscopic Ivor-Lewis for esophageal cancer: propensity score-matched analysis

Addressing the unmet need for a comprehensive lung cancer registry in Romania